Rose, Olaf http://orcid.org/0000-0003-1681-4909
Happe, Svenja
Huchtemann, Tessa
Mönig, Constanze
Ohms, Michael
Schwalbe, Oliver
Warnecke, Tobias
Erzkamp, Susanne
Article History
Received: 4 February 2021
Accepted: 26 March 2021
First Online: 23 April 2021
Declarations
:
: Susanne Erzkamp has received a speaker honorarium from MSD Sharp & Dohme, Svenja Happe has received lecturer honoraria from Bial, Bioprojet and Bayer Vital, Tessa Huchtemann declares that she has no competing interests, Constanze Mönig declares that she has no competing interests, Michael Ohms declares that he has no competing interests, Oliver Schwalbe declares that he has no competing interests, Olaf Rose has received a speaker honorarium from AbbVie, MSD Sharp & Dohme, Novartis and Omnicell, Tobias Warnecke has received lecturer and consulting honoraria from AbbVie, UCB Pharma, Archimedes, Bayer, Bial, Biogen, Desitin, Licher, Phagenesis, Pfizer, Teva, and Zambon.
: The study was not obtained as no patient data was used in this publication.
: was not obtained as no patient data were used in this publication